Aspirin desensitization in aspirin intolerance: Update on current standards and recent improvements

Current Opinion in Allergy and Clinical Immunology

Volumn 6, Issue 3, 2006, Pages 161-166

  Pfaar, Oliver ^a   Klimek, Ludger ^a  

^a Center for Rhinology and Allergology   (Germany)

Author keywords

Acetylsalicylic acid; Aspirin desensitization; Aspirin intolerance; Aspirin sensitivity; Nasal polyps; Samter triad

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; DICLOFENAC; DIFLUNISAL; ETODOLAC; FENOPROFEN; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; LIPOXYGENASE; MECLOFENAMIC ACID; MEFENAMIC ACID; MELOXICAM; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYPHENBUTAZONE; PARACETAMOL; PHENYLBUTAZONE; PIROXICAM; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; SALSALATE; SULINDAC; TOLMETIN; UNINDEXED DRUG;

ASTHMA; CLINICAL TRIAL; DESENSITIZATION; DIAGNOSTIC TEST; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; HUMAN; HYPERSENSITIVITY; MEDICAL LITERATURE; NOSE CONGESTION; NOSE POLYP; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; RHINORRHEA; RHINOSINUSITIS; STANDARDIZATION; TREATMENT OUTCOME; CHEMICALLY INDUCED DISORDER; DRUG HYPERSENSITIVITY; IMMUNOLOGY; METHODOLOGY; PREVALENCE;

ASPIRIN; ASTHMA; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; HUMANS; NASAL POLYPS; PREVALENCE;

EID: 33745576515     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/01.all.0000225153.45027.6a     Document Type: Review

References (37)

1. Widal MF, Abrami P, Lenmoyez J. Anaphylaxis and idiosyncrasy [in French]. Presse Med 1922; 30:189-192.
2. Samter M, Beers RF. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med 1968; 68:975-983.
3. Babu KS, Salvi S. Aspirin and asthma. Chest 2000; 118:1470-1478.
4. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003; 111:913-921.
5. Szczeklik A, Sanak M, Niz E, Kielbasa B. Aspirin intolerance and the cyclooxygenase-leukotriene pathways. Curr Opin Pulm Med 2004; 10:51-56.
6. Hedman J, Kaprio J, Poussa T, et al. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a populationbased study. Int J Epidemiol 1999; 28:717-722.
7. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J 2000; 16:432-436.
8. Berges-Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2002; 89:474-478.
9. Marquette CH, Saulnier F, Leroy O, et al. Long-term prognosis for near-fatal asthma. A 6-year follow-up study of 145 asthmatic patients who underwent mechanical ventilation for near-fatal attack of asthma. Am Rev Respir Dis 1992; 146:76-81.
10. Rosado A, Vives R, Gonzalez R, et al. Can NSAIDs intolerance disappear? A study of three cases. Allergy 2003; 58:689-690.
11. Szczeklik A, Nizankowska E. Clinical features and diagnosis of aspirin induced asthma. Thorax 2000; 55 (Suppl. 2):S42-S44.
12. Bachert C, Watelet JB, Gevaert P, Van Cauwenberge P. Pharmacological management of nasal polyposis. Drugs 2005; 65:1537-1552.
13. Picado C, Mullol J. The nose in aspirin-sensitive asthma. In: Szczeklik A, Gryglewski RJ, Vane J, editors. Eicosanois, aspirin and asthma. New York: Marcel Dekker; 1998. pp. 493-505.
14. Molnar-Gabor E, Endreffy E, Rozsasi A. HLA-DRB1, -DQA1, and -DQB1 genotypes in patients with nasal polyposis. Laryngoscope 2000; 110:422-425.
15. Kowalski ML, Grzegorczyk J, Pawliczak R, et al. Decreased apoptosis and distinct profile of infiltrating cells in the nasal polyps of patients with aspirin hypersensitivity. Allergy 2002; 57:493-500.
16. Pawliczak R, Lewandowska-Polak A, Kowalski ML. Pathogenesis of nasal polyps: an update. Curr Allergy Asthma Rep 2005; 5:463-471. This paper gives a recent update on the pathogenesis of nasal polyps, with a focus on aspirin-sensitive patients.
17. Min JW, Jang AS, Park SM, et al. Comparison of plasma eotaxin family level in aspirin-induced and aspirin-tolerant asthma patients. Chest 2005; 128: 3127-3132.
18. Gosepath J, Brieger J, Mann WJ. New immunohistologic findings on the differential role of cyclooxygenase 1 and cyclooxygenase 2 in nasal polyposis. Am J Rhinol 2005; 19:111-116.
19. Jantii-Alanco S, Holopainen E, Malmberg H. Recurrence of nasal polyps after surgical treatment. Rhinology 1989; 8:59-64.
20. Albu S, Tomescu E, Mexca Z, et al. Recurrence rates in endonasal surgery for polyposis. Acta Otorhinolaryngol Belg 2004; 58:79-86.
21. Cowburn AS, Sladek K, Soja J, et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998; 101:1-13.
22. Stevensson DD, Simon RA. Sensitivity to aspirin and nonsteroid anti-inflammatory drugs. In: Middleton E, Reed CE, Ellis EF, et al., editors. Allergy: principle and practice, vol. 2. St. Louis, Missouri: Mosby-Year Book; 1993. pp.1747-1765.
23. Milewski M, Mastalerz L, Nilzankowska E. Nasal provocation test with lysineaspirin for diagnosis of aspirin-sensitive asthma. J Allergy Clin Immunol 1998; 101:581-586.
24. Morwood K, Gillis D, Smith W, Kette F. Aspirin-sensitive asthma. Int Med J 2005; 35:240-246.
25. Stevenson DD, Simon RA. Lack of cross reactivity between Rofecoxib and aspirin-sensitive patients with asthma. J Allergy Clin Immunol 2001; 108: 47-51.
26. Zeiss CR, Lockey RF. Refractory period to aspirin in a patient with aspirin-induced asthma. J Allergy Clin Immunol 1976; 57:440-448.
27. Stevenson DD, Simon RA, Mathison DA. Aspirin-sensitive asthma: tolerance to aspirin after positive oral aspirin challenges. J Allergy Clin Immunol 1980; 66:82-88.
28. Parikh AA, Scadding GK. Intranasal lysine-aspirin in aspirin-sensitive nasal polyposis: a controlled trial. Laryngoscope 2005; 115:1385-1390. A recent study focusing on the favourable effects of aspirin desensitization on nasal polyps in aspirin-sensitive patients.
29. Patriarca G, Schiavino D, Nucera E, et al. Prevention of relapse in nasal polyposis. Lancet 1991; 337:1488.
30. Schmitz-Schumann M, Schaub E, Virchow C. Inhalation provocation test with lysine-acetylsalicylic acid in patients with analgetics-induced asthma. Prax Klin Pneumol 1982; 36:17-21.
31. Stevenson DD, Pleskow WW, Simon RA, et al. Aspirin-sensitive rhinosinusitis asthma: a double blind cross over study of treatment with aspirin. J Allergy Clin Immunol 1984; 73:500-507.
32. Sweet J, Stevenson DD, Simon RA, Mathison DA. Long-term effects of aspirin desensitization - treatment for aspirin-sensitive rhinosinusitis-asthma. J Allergy Clin Immunol 1990; 85:59-65.
33. Stevenson DD, Hankammer MA, Mathison DA, et al. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes. J Allergy Clin Immunol 1996; 98:751-758.
34. Berges-Gimeno P, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2003; 111:180-186.
35. Juergens UR, Christiansen SC, Stevenson DD, Zuraw BL. Inhibition of monocyte leukotriene B4 production following aspirin desensitization. J Allergy Clin Immunol 1995; 96:148-156.
36. Arm JP, Austen KF. Leukotriene receptors and aspirin sensitivity. N Engl J Med 2002; 347:1524-1526.
37. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium-salicylate and aspirin. Science 1994; 265:956-959.